Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

28.65 -0.30 (-1.04%)
Streaming Delayed Price Updated: 3:50 PM EST, Dec 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcutis Biotherapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
This Biotech Stock Could Cure Your Portfolio's Pain ↗
A combination of a relatively low-risk approval process, growing sales, and a very attractive valuation based on management's peak sales estimations makes this biotech stock attractive. 
Via The Motley Fool
News headline image
ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) Shows Strong Technical and Fundamental Momentum ↗
Arcuitis Biotherapeutics (ARQT) exemplifies a high-growth momentum stock in a confirmed technical uptrend, blending strong fundamentals with a robust price structure. 
Via Chartmill
News headline image
Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Why Shares in Arcutis Biotherapeutics Surged Again This Week ↗
The company continues to receive good news from the Food and Drug Administration. 
Via The Motley Fool
News headline image
Earnings Scheduled For October 28, 2025 ↗
 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Peering Into Arcutis Biotherapeutics Inc's Recent Short Interest ↗
 
Via Benzinga
News headline image
Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) Combines Strong Trend with High-Growth Momentum ↗
ARQT stock combines a strong Minervini Trend Template setup with explosive sales and earnings growth, creating a compelling high-growth momentum opportunity. 
Via Chartmill
News headline image
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
These stocks are moving in today's session ↗
Stay up-to-date with the latest market trends one hour before the close of the markets on Tuesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
Arcutis Q3 2025 Earnings Call Transcript ↗
Arcutis Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Top stock movements in today's session. ↗
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Crude Oil Falls Over 2%; PayPal Shares Spike Higher ↗
 
Via Benzinga
News headline image
Here's Why This Biotherapeutics Company's Stock Surged Higher by 30% Today ↗
Arcutis Biotherapeutics had an excellent update for investors and its future looks bright. 
Via The Motley Fool
News headline image
Arcutis Tops A Profit-Taking Zone After Smashing Forecasts. But There Was Another Surprise. ↗
Arcutis Biotherapeutics smashed quarterly calls Tuesday and reported its first-ever positive net income. 
Via Investor's Business Daily
News headline image
Traders are paying attention to the gapping stocks in Tuesday's session. ↗
Traders are paying attention to the gapping stocks in Tuesday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
News headline image
Wayfair, Qorvo, Celestica, United Parcel Service, Regeneron Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Reports Strong Q3 2025 Earnings Beat and Return to Profitability ↗
Arcutis (ARQT) Q3 2025 earnings crush estimates with a surprise profit. Revenue of $99.2M beats forecasts, driving the stock up 16% on strong ZORYVE demand. 
Via Chartmill
Topics Earnings
News headline image
Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Uncovering Potential: Arcutis Biotherapeutics's Earnings Preview ↗
 
Via Benzinga
News headline image
Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE® (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology Conference
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Allure Magazine Honors Arcutis’ ZORYVE® (roflumilast) with Prestigious Best of Beauty Breakthrough Award
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.